A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

Not Recruiting

Trial ID: NCT05351554


A Randomized, Double-blind, Placebo-controlled, Study with an Open-label Cohort.

Official Title

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis

Stanford Investigator(s)

Matthew C. Baker, MD MS
Matthew C. Baker, MD MS

Assistant Professor of Medicine (Immunology and Rheumatology)


Inclusion Criteria:

   - Male or female age ≥18 years

   - Able and willing to provide written informed consent, which includes compliance with
   study requirements and restrictions listed in the consent form

   - History of documented sarcoidosis (must include histological confirmation, from any
   organ, in the subject's medical history or records)

   - Meet Heart Rhythm Society Cardiac Sarcoid Diagnostic Criteria (modified)

   - Female subjects must agree to use an approved highly effective birth control (BC)

   - Male subjects must agree to, and attest that, female partners of childbearing
   potential are using one of the allowed highly effective methods of contraception

   - Body Mass Index (BMI) <40 kg/m2 at Screening.

   - Vaccination for COVID-19 with completion of the primary series at least 2 weeks prior
   to randomization

Exclusion Criteria:

   - Hospitalized for any respiratory or cardiac illness ≤30 days prior to Screening

   - Known pulmonary hypertension requiring therapy

   - Autoimmune disease other than sarcoidosis likely to require treatment during the
   subject's participation in this study

   - Symptoms and/or signs of extracardiac sarcoidosis that are likely to warrant treatment
   in addition to that required for the subject's cardiac disease

   - Estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m2 (Modification of Diet
   in Renal Disease [MDRD] equation) or requiring renal replacement therapy

   - Hemoglobin ≤9.5 g/dL

   - Participation in another interventional clinical trial within 6 months prior to
   Screening and throughout the duration of participation in this study

   - Systolic blood pressure (SBP) <90 or >180 mm Hg; Diastolic blood pressure (DBP) <60 or
   >110 mm Hg at Screening

   - Has documented laboratory-confirmed severe acute respiratory syndrome coronavirus-2
   (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) or other
   approved clinical testing ≤3 months prior to randomization

   - Significant valvular heart disease known or anticipated to require surgical repair or
   replacement during the subjects' participation in this study

   - Female subjects who are pregnant or breastfeeding or intend to be, during the study

   - History of severe allergic or anaphylactic reactions to therapeutic proteins or known
   sensitivity to namilumab or to its inactive components

   - Any other acute or chronic medical condition, that in the judgment of the Investigator
   or Sponsor, may increase the risk associated with study participation or
   investigational product administration, or may interfere with the interpretation of
   study results, and would make the participant inappropriate for entry into this study

Other protocol-defined inclusion/exclusion criteria may apply.


drug: Namilumab

drug: Placebo

drug: Open label Namilumab

drug: Prednisone

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Angie Aberia